Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
The judges have completed their scoring and the Scrip Awards 2023 shortlist has now been announced! Visit our website to see who has the chance of winning a prestigious Award this year. The winners will be revealed at the ceremony on Thursday, 16 November.
BEST ONCOLOGY R&D ADVANCE *NEW*
This new Scrip Award seeks to recognize early clinical advances in oncology made by small biopharma companies. The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.
This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.
FINALISTS
AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy
Arvinas and Pfizer’s oral PROteolysis TArgeting Chimera (PROTAC) ER degrader vepdegestrant for breast cancer
Avacta Therapeutics’ AVA6000 pre|CISION tumour-targeted chemotherapy
Immuneering’s deep cyclic inhibition candidate IMM-1-104 for advanced RAS-mutant solid tumors
Kura Oncology’s menin inhibitor ziftomenib for multiple genetic subsets of acute myeloid leukemia
MSD/Moderna’s mRNA-4157/V940 investigational personalized mRNA cancer vaccine.
COVID-19 Tests
Beginning September 25, every U.S. household can again place an order to receive four more free COVID-19 rapid tests delivered directly to their home. Before You Throw Out "Expired" Tests: Check to see if your COVID-19 tests' expiration dates have been extended.
The COVIDtests.gov program has distributed over 755 million tests directly to more than two-thirds of American households, 310 million of which went to households in underserved communities.
Will be a very interesting afternoon, price range will be squeezed to 138-42.
The value of the therapeutic division, pipeline, deals etc. will make Avacta the hottest Precision Oncology IPO over the next couple of months.
NY and the majors will be up early and a revaluation of the SOP will make/force the “ size buyers” to step up a gear, before they loose out to a therapeutic buyer.
Dr. Tap will be very interested in this event.
https://x.com/sarcoma_uk/status/1701007924255179157?s=43&t=mz9Nha6Zg_v-PthdergF2Q